1 citations
,
May 2010 in “Nursing Standard” Treatments for autoimmune hair loss have limited success and patients need emotional support and self-acceptance.
July 2026 in “Pediatric Dermatology” Young patients with alopecia areata are satisfied with Janus kinase inhibitors, noting hair regrowth and improved quality of life.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
June 2026 in “Current Opinion in Pediatrics” Early, tailored assessment and treatment are crucial for adolescent hair loss, with promising new diagnostic and treatment options.
June 2026 in “British Journal of Dermatology” JAK inhibitors can cause severe acne, limiting their use for hair regrowth.
April 2026 in “AMEI's Current Trends in Diagnosis & Treatment” PCOS-related infertility is managed with lifestyle changes and medications.
March 2026 in “Acta Dermato Venereologica” Lower illness acceptance is linked to more body dysmorphic disorder symptoms in patients with body modifications.
March 2026 in “Anais Brasileiros de Dermatologia” Facial aesthetic procedures improve quality of life for transgender individuals.
February 2026 in “Expert Review of Endocrinology & Metabolism” Early identification and personalized treatment of skin issues in PCOS are crucial for better outcomes.
February 2026 in “Psychoneuroendocrinology” Lower family income is linked to more stress in parents and more behavior problems in children.
Gender-diverse individuals face more depression and anxiety, possibly due to unique stress profiles.
February 2026 in “Journal of Drugs in Dermatology” Janus kinase inhibitors are effective and safe for treating alopecia areata.
January 2026 in “Dermatology Practical & Conceptual” Diffuse lichen planopilaris greatly reduces quality of life.
December 2025 in “Journal of Cosmetic Dermatology” Finasteride does not increase the risk of depression or suicide.
December 2025 in “BJPsych Open” Semaglutide may worsen eating disorders in vulnerable individuals.
November 2025 in “Frontiers in Psychiatry” People with androgenetic alopecia often experience more anxiety, depression, and lower self-esteem.
November 2025 in “Journal of Laboratory Medicine” Chronic stress increased after lockdown, especially in young adults and females.
October 2025 in “COGNITIONIS Scientific Journal” Postpartum hair loss is common, temporary, and linked to hormonal changes, stress, and nutrition.
October 2025 in “Reactions Weekly” Finasteride and dutasteride may cause depression and suicidal thoughts.
September 2025 in “Obstetrics and gynecology.” Myoinositol effectively manages PCOS with fewer side effects than metformin.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
August 2025 in “Journal of Affective Disorders” Gender-diverse people face more depression and anxiety, partly due to stress and lower cortisol levels.
Social Botox and societal beauty standards negatively impact adolescent self-image, influenced by social media and cultural pressures.
June 2025 in “British Journal of Dermatology” Better diagnostic and treatment strategies are needed for acne keloidalis nuchae, especially in high-risk groups.
June 2025 in “Pharmaceuticals” Finasteride use may increase suicidality risk, especially in young men.
June 2025 in “Canadian dermatology today.” Alopecia areata deeply affects self-esteem and identity, needing both medical and emotional support.
June 2025 in “Reactions Weekly” Finasteride may increase the risk of depression and suicidal thoughts.
April 2025 in “Physical and Engineering Sciences in Medicine” PCOS forum users view lifestyle changes and supplements positively, but have mixed feelings about contraceptive pills.
March 2025 in “Journal of the American Academy of Dermatology” Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.
March 2025 in “Annals of Medicine and Surgery” PCOS skin symptoms need personalized treatment and psychological support to improve quality of life.